Moderna Launches New Venture Valera LLC for Infectious Diseases
Advertisement
Moderna Therapeutics announced the launch of Valera LLC, a new Moderna venture focused exclusively on the advancement of vaccines and therapeutics for the prevention and treatment of viral, bacterial and parasitic infectious diseases.
The vaccines work of Valera builds on a body of preclinical research at Moderna showing the ability of modified mRNA to express viral antigens in vivo and to induce robust immune responses. Valera's therapeutic passive immunity programs will expand on Moderna's research using mRNA to express antibodies that bind to viral and other targets. The robust data from these programs across a range of preclinical infectious disease models, together with the inherent, rapid turn-around time in creating novel mRNA constructs, provide Valera with a potentially powerful and versatile new platform for the creation of a broad array of vaccines and passive immunity therapies.
"We are thrilled to launch Valera to bring sharp focus to developing mRNA Therapeutics for a wide range of infectious diseases, which remain a hugely significant global health threat," said Stephane Bancel, president and CEO of Moderna. "We believe that mRNA offers unique advantages when it comes to the rapid design and manufacture of new vaccines and therapies, and we have seen promising signs of efficacy in our preclinical work."
Mr. Bancel will continue to serve as interim president of Valera. Moderna has engaged the global executive search firm Korn Ferry to recruit a president for Valera.
Giuseppe Ciaramella, Ph.D., former vice president and head of immunology and biotherapeutics at Moderna, will serve as chief scientific officer of Valera. Dr. Ciaramella has nearly two decades of global industry experience at AstraZeneca, Boeringher Ingelheim, Pfizer and Merck focused on the discovery and development of small molecule and biological clinical candidates, with a particular focus on antivirals and biotherapeutics. The plan in 2015 is for Dr. Ciaramella to hire and lead a team of 15 scientists to drive early-stage discovery and development at Valera.
Michele Keough, formerly with Moderna's R&D strategy and operations group, will serve as head of programs and alliance management at Valera. Prior to Moderna, Ms. Keough served as senior director, program and alliance management at Genzyme, a Sanofi company, where she led several of Genzyme's strategic partnerships with biotechnology companies.
Moderna is actively recruiting for the position of chief medical officer of Valera.
Other news from the department business & finance
Most read news
More news from our other portals
Last viewed contents
In the heat of the wound - Smart bandage
Sartorius opens new Center of Excellence for bioanalytics in Ann Arbor - Manufacturing of instruments, consumables and reagents for cell and protein analysis
CyBio and Macherey-Nagel collaborate to develop applications for automated DNA/RNA preparation
Innovations for Health: When Molecular Spectroscopy Meets Lasers and Photonics - "An all-optical, minimally invasive and label-free diagnostic tool could represent a significant advance in health..."
HI viruses crack the lock to the cell nucleus - For the first time, researchers have observed how HIV penetrates the nuclear pores to the genome of human immune cells
Closure of Astellas CNS research in Edinburgh
Antibody discovered that blocks almost all known HIV variants in neutralization assays - The discovery potentially opens up new perspectives for the prevention and treatment of HIV infections
New method for measuring luminescence lifetime offers breakthrough in scientific imaging - Accelerating the pace of discovery in science and industry
Decreasing biodiversity may promote spread of viruses - New insight into the dynamics of infectious disease
Mysthera Therapeutics Launches to Develop First-in-Class Autoimmune Disease Therapies - Seed Capital from Forty51 Ventures to Advance Pipeline of Pan-PIM Kinase Inhibitors
3D-printed pills with desired drug release – a step upwards in medication - Funny looking pills are not a design gimmick, they can release medication in a desired time regime!
